Objective: To evaluate the outcome of using radiotherapy (RT) alone to treat patients with early-stage Hodgkin’s disease (HD). Method: The records of 28 patients with HD treated with RT alone at Kuwait Cancer Control Center between 1980 and 1998 were reviewed. Results: Twenty-three patients had stage I HD and 5 stage II. Two patients had B symptoms, 12 (42.9%) patients lymphocyte-predominant histology, 9 (32.1%) nodular sclerosis and 7 (25%) mixed cellularity. Overall survival and relapse-free survival at 10 years were 100 and 83%, respectively. Conclusion: Our data indicate that the use of RT alone for treatment of early stages of HD appears to be effective.
14156 Background: Bevacizumab is being used in combination with five fluorouracil(5-FU) based chemotherapy like FOLFIRI, FOLFOX, and capecitabine, since its inception in the treatment of metastatic colorectal cancer one year ago. Methods: a retrospective analysis was carried out to assess the toxicity profile of bevacizumab. Results: total 36 patients received bevacizumab in combination with various 5-FU based regimens .Twenty one were males 15 were females. A total of 288 cycles have been administered. Toxicities included change in medication for uncontrolled hypertension and mild epistaxis in 3 cases. One patient with intact primary in sigmoid colon developed perforation, peritonitis and she died subsequently. Conclusions: Conclusion- this preliminary results indicate that bevacizumab in combination with 5-FU based chemotherapy was tolerated. Extra precaution is required in cases of intact primary tumours. No significant financial relationships to disclose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.